AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-804-8272524
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings DateN/A
OptionableNot Optionable
Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is Ampliphi Biosciences' stock symbol?
Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were Ampliphi Biosciences' earnings last quarter?
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. View Ampliphi Biosciences' Earnings History.
What price target have analysts set for APHB?
1 brokerages have issued 12 month target prices for Ampliphi Biosciences' stock. Their forecasts range from $3.50 to $3.50. On average, they expect Ampliphi Biosciences' share price to reach $3.50 in the next twelve months. View Analyst Price Targets for Ampliphi Biosciences.
What is the consensus analysts' recommendation for Ampliphi Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampliphi Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ampliphi Biosciences.
Has Ampliphi Biosciences been receiving favorable news coverage?
Headlines about APHB stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ampliphi Biosciences earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Ampliphi Biosciences.
Who are some of Ampliphi Biosciences' key competitors?
Some companies that are related to Ampliphi Biosciences include Paradigm Biopharmaceuticals (PAR), Starpharma (SPL), BELLUS Health (BLU), TELIX Pharmaceutical (TLX), Biotest (BIO), Oxford BioMedica (OXB), Theratechnologies (TH), Bellus Health (BLU), Neptune Wellness Solutions (NEPT), Resverlogix (RVX), ProMetic Life Sciences (PLI), Rafael (RFL), Silence Therapeutics (SLN), Pfenex (PFNX) and CEL-SCI (CVM).
What other stocks do shareholders of Ampliphi Biosciences own?
Who are Ampliphi Biosciences' key executives?
Ampliphi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, CEO & Director (Age 61)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 58)
- Mr. Michael Scott Salka, Consultant (Age 57)
How do I buy shares of Ampliphi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
How big of a company is Ampliphi Biosciences?
What is Ampliphi Biosciences' official website?
How can I contact Ampliphi Biosciences?
Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for Ampliphi Biosciences (NYSEAMERICAN APHB)
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
